Isis Pharmaceuticals’ License Agreement with Bayer for ISIS-FXI Rx Receives Hart-Scott-Rodino Approval

ByConnor Hodde

Isis Pharmaceuticals, Inc. (ISIS) today announced that its license agreement with Bayer HealthCare (Bayer) to develop and commercialize ISIS-FXIRx has received clearance under the Hart-Scott-Rodino Antitrust Improvements Act.  After completion of ongoing activities at Isis, Bayer will assume all global clinical development as well as worldwide regulatory and commercialization responsibilities for ISIS-FXIRx.  ISIS-FXIRx is an antisense drug in development for the prevention of clotting disorders.

Read the entire article here.

Similar Posts

Retinopathy Prevalence Decreasing in Diabetic Adolescents

ByConnor Hodde

A 20-year observational study has chronicled notable declines in retinopathy for young patients with type 1 diabetes who receive intensive glycemic control therapy, confirming earlier findings that found a link between normalized blood glucose levels and the slower progression of eye, kidney, and nerve damage.  http://www.medscape.com/viewarticle/752133

Tiny Nanoparticles Could Make Big Impact for Cornea Transplants

ByConnor Hodde

There are about 48,000 corneal transplants done each year in the U.S., compared to approximately 16,000 kidney transplants and 2,100 heart transplants 12. Out of the 48,000 corneal transplants done, 10 percent of them end up in rejection, largely due to poor medication compliance.  The nanoparticle loaded with medication could eliminate the need for a…

American Health Assistance Foundation Announces Latest Grants to Advance Promising Vision Research

ByConnor Hodde

  The American Health Assistance Foundation (AHAF), a nonprofit organization with a history of funding breakthrough research on age-related vision diseases, announced today that it has awarded 21 new grants totaling $2.1 million to scientists worldwide who are studying and macular degeneration. The two conditions are the leading causes of irreversible blindness in the world….

Solving Three Major Age-related Eye Conditions in One Go

ByConnor Hodde

Vascular endothelial growth factor A (VEGF-A) is looking like more of an optical troublemaker than ever before – as well as its link with wet age-related macular degeneration (AMD), it also might be causing dry AMD and even age-related cataracts.  Therefore, Massachusetts General Hospital researcher and paper author, Dr Alexander Marneros, is looking at what processes…

EyeCRO Contributes to LUXTURNA® Potency Assay Validation

ByConnor Hodde

We’re proud to share that EyeCRO CEO Dr. Rafal Farjo is a co-author on a new publication validating a cell-based potency assay for LUXTURNA®, the first gene therapy approved in the U.S. for an inherited retinal disease. As stated in the publication: “This represents the first report of validation studies supporting an in vitro cell-based…